A5050827309- Multiple Myeloma Research and Treatments
- Glioma Diagnosis and Treatment
- Immune cells in cancer
- Ocular Oncology and Treatments
- Single-cell and spatial transcriptomics
- Metabolomics and Mass Spectrometry Studies
- Cancer, Hypoxia, and Metabolism
- Telomeres, Telomerase, and Senescence
- Virus-based gene therapy research
- Infectious Diseases and Mycology
- Medical Imaging Techniques and Applications
- Extracellular vesicles in disease
- Veterinary Oncology Research
University of Pisa
2022-2025
Fondazione Pisa
2022-2025
German Cancer Research Center
2023
Heidelberg University
2023
Glioblastoma (GB) is the most severe form of brain cancer, with a 12-15 month median survival. Surgical resection, temozolomide (TMZ) treatment, and radiotherapy remain primary therapeutic options for GB, no new therapies have been introduced in recent years. This standstill primarily due to preclinical approaches that do not fully respect complexity GB cell biology fail test efficiently anti-cancer treatments. Therefore, better treatment screening are needed. In this study, we developed...
Abstract Background Glioblastoma (GB) is the most severe form of brain cancer, with a 12-15 month median survival. Surgical resection, temozolomide (TMZ) treatment, and radiotherapy (RT) remain primary therapeutic options for GB, no new therapies have been introduced in recent years. This standstill primarily due to preclinical approaches that do not fully respect complexity GB cell biology fail test efficiently anti-cancer treatments. Therefore, better treatment screening are needed. In...
Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: Multiple myeloma (MM) is one of the most common hematological malignancies, accounting for 20% all newly diagnosed cancers. The recent data from Globocan show that in 2020, worldwide, number new cases was 159,985. Although current 5-year survival rate over 50% MM still considered an incurable disease since patients eventually relapse. Presence RAS genes reported about 75% relapsed/refractory...